Oncology Today with Dr Neil Love cover image

HER2-Positive Gastrointestinal Cancers — Microlearning Activity 2: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium

Oncology Today with Dr Neil Love

00:00

Choosing HER2 therapy after frontline BTC

Panelists compare trastuzumab combinations, tucatinib, T-DXd and zanidatamab for second-line HER2-positive biliary cancers.

Play episode from 04:38
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app